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self-tolerance in SLE within the context of immune-profiling and repertoire sequencing, but with a primary focus on work from our lab and its overall contribution to the field. We describe the power of AIRR-seq and integrated transcriptional and epigenetic analyses to identify novel B-cell populations and catalogue conventional and newly defined cell populations within different B-cell differentiation pathways. In this context, we will discuss data derived in our laboratory from a multitude of SLE patients and from other autoimmune diseases, as well as healthy vaccinated individuals. We will demonstrate distinctive repertoire features of SLE antibody secreting cells (ASC), including higher diversity and lower rate of somatic 
| DEFINING B-CELL TOLER AN CE THROUG H REPERTOIRE S TUD IE S IN HUMAN AUTOIMMUNIT Y
Defective B-cell tolerance for self-antigens, leading to the generation of pathogenic, isotype-switched autoantibodies, is at the center of multiple human autoimmune diseases and is critical, in particular, for the development of SLE. Indeed, SLE is a quintessential systemic autoimmune disease characterized by high abundance of the most diverse array of autoantibodies among any human autoimmune condition. 6 Such promiscuity points to generalized defects in B-cell regulation underlying a proclivity to generate productive responses to multiple self-antigens, rather than a narrow B-cell dysregulation induced by a particularly immunogenic antigen. This scenario is supported by the concentration of disease risk alleles on B-cell signaling pathways. 7, 8 In contrast to SLE, 
| CENTR AL QUE S TI ON S AND CHALLENG E S IN UNDER S TANDING AUTOIMMUNE B-CELL RE S P ON S E S IN S LE
Human B-cell tolerance is enforced through different mechanisms, prominently including deletion, anergy, and receptor editing. 1 These mechanisms operate at multiple checkpoints during early bone marrow (BM) B-cell development and lead to the establishment in healthy subjects of a mature naive B-cell compartment of decreased autoreactivity relative to the primary, unselected antibody repertoire expressed by newly emerging immature B cells. 9 Yet, even in healthy subjects the mature naive B-cell compartment is still endowed with a significant degree of autoreactivity, thereby imposing the need for additional peripheral tolerance checkpoints. 10 Such late checkpoints are enforced throughout B-cell activation and differentiation into ASC. 11, 12 Particularly important is to avoid differentiation into long-lived plasma cells (LLPC), that survive indefinitely within the BM microenvironment in a B-cell autonomous fashion and are typically refractory to existing therapies including B-cell depletion.
Thus far, the experimental approach to understanding defective checkpoints in human autoimmunity has relied upon measuring the frequency of autoreactivity using monoclonal antibodies (mAb) generated from single cells sorted from B-cell populations representing distinct stages of differentiation/activation and purified according to accepted surface markers. 9 This approach has defined substantial contraction of autoreactivity during maturation of transitional cells into naive B cells only for the same level of autoreactivity to be restored into the isotype-switched memory compartment through SHM during the GC reaction.
11
Subsequently, autoreactive memory cells are limited in their ability to differentiate into BM LLPC at late peripheral checkpoints.
12
While highly informative, these approaches have suffered from low throughput (the analysis being limited to a few hundred cells) and are limited to general ANA (anti-nuclear antibodies) and DNA.
While still limited to global ANA reactivity, much higher throughput has been recently achieved by a flow-based assay that documented progressive attrition of ANA-reactive B cells through peripheral checkpoints, resulting in a very low frequency within the isotype-switched memory compartment. Interestingly, however, SLE subjects were able to enforce the same level of ANA censoring as healthy controls with the notable exception of the anergic naive compartment which contained higher levels of autoreactive B cells in healthy subjects. 13 Finally, a combination of flow cytometry, next generation sequencing (NGS), and single cell mAb analyses has been used to understand the fate of intrinsically autoreactive 9G4+ B cells expressing autoantibodies encoded by VH4-34. 1 These studies identified GC censoring as an important tolerance mechanism either through deletion or mutation away from the germline-encoded autoreactivity. 14, 15 These mechanisms are defective in SLE thereby explaining the high levels of serum 9G4 autoantibodies observed in SLE in a disease-specific fashion.
14,15
| B-CELL AND ANTIBODY REPERTOIRE S IN S LE
As discussed, the subversion of immunological tolerance underpins the development of autoimmune disorders. Thus, tolerance breakdown enables clonal expansion and affinity maturation of B cells reacting with self-antigens, ultimately leading to positive selection of pathogenic B cells and plasma cells (PC). In turn, the generation of pathogenic autoantibodies cause tissue damage either through inflammatory immune complexes or in situ binding to tissue antigens.
These processes evolve in an antigen-driven fashion through critical molecular changes that include isotype-switching from IgM to more pathogenic IgG subclasses and SHM. While the molecular basis of these processes is well understood, a precise delineation of their participation in human autoimmunity has been hampered by experimental limitations with most studies restricted to a relatively low number of mAb at a single point in time. Moreover, studies have centered on predetermined self-antigens believed to represent disease targets such as DNA in SLE. 16 Of note, however, the actual nature of the antigens that trigger the initial tolerance breakdown in naive B cells remains to be clarified. 17 Different studies have established that the unmutated germline version of high-affinity IgG autoantibodies of known specificity generally loses autoreactivity. 10 This observation is consistent with sequential selection of pathogenic clones that starts with an unrecognized self-antigen (or cross-reactive foreign antigen), followed by selection against a separate antigen. 18 A nonmutually exclusive alternative model would implicate a generalized process of naive B-cell activation in SLE and stochastic acquisition of pathogenic autoreactivity through SHM and selection by selfantigen within the GC, an environment specialized in prolonged antigen presentation and cyclical clonal expansion which is rich in self-antigens in part due to high levels of apoptosis and defective apoptotic cell clearance. Another possibility, described in the mouse anti-DNA response, 19, 20 is that after being first stimulated by a triggering antigen, autoreactive B cells would subsequently acquire a separate autoreactivity against a different self-antigen (target antigen), through SHM either in the GC 21 or in the local environment of target tissues such as the kidney in patients with lupus nephritis. 22 Indeed, this process could also help explain the well-documented phenomenon of epitope spreading responsible for the progressive addition of antigenic targets leading to disease development and progression. 23 Our work, reviewed below, suggests that an ongoing incorporation of new naive B-cell clones into the autoreactive repertoire is central to the pathogenesis of SLE. [24] [25] [26] To that end, the antibody repertoire of tissue-resident PC needs to be characterized and matched with the one expressed by systemic cells, and clones shared between the two compartments should be then analyzed for evidence of affinity maturation and/or a shift in autoreactivity to understand maturation and antigenic targets within the kidney.
| INTEG R ATING REPERTOIRE ANALYS IS INTO A B-CELL IMMUNOMI C S APPROACH TO S LE
Already some groups have begun to lay a foundation for these studies by analyzing the clonal makeup and connectivity of B cells from various tissues in the human body with remarkable results. 27, 28 Addressing these questions requires a comprehensive experi- 
| UNDER S TANDING THE CELLUL AR BA S IS OF AUTOANTIBODY G ENER ATI ON IN H UMAN S LE
As previously discussed, a central question in SLE is understanding the antigenic and molecular events leading to B-cell activation, breakdown of tolerance, and differentiation either into long-lived memory cells and PC or short-lived plasmablasts (PB). As also previously indicated, most extant studies in human SLE have been limited in scope without extensive repertoire analysis. We have started to address these issues through the combined B-cell immunomics approach described earlier in this review to understand the properties and cellular origin of the ASC and their contribution to changes in serum autoantibodies. During lupus flares, large numbers of newly generated, proliferative ASC are released into the periphery after being generated in secondary lymphoid tissues through either antigen specific or polyclonal stimulation, 41 a process seemingly similar to vaccine recall ASC responses that peak 6-10 days after immunization. 42 Through the use of single cell experiments, it has been shown that postvaccination ASC are oligoclonal in nature with up to 80% being antigen-specific, a 100-to 800-fold enrichment from preimmunization levels. Multiple studies indicate that these changes result from activation of pre-existing antigen-specific memory cells. F I G U R E 3 (A) Mean mutation frequencies of clones identified in Naive, isotype-unswitched memory (UnSw), isotype-switched memory (SwM), and antibody secreting cells (ASC) show a significantly lower frequency of somatic mutation in ASC collected from SLE subjects (B) Sequences with less than three total mutations in the variable (V) region were identified in SwM and ASC populations and plotted as a percent of total sequences (n = 16 healthy naive; 14 SLE naive; four healthy UnSw; six SLE UnSw; 16 healthy SwM; 29 SLE SwM; 14 healthy ASC; 11 SLE ASC; *P < .05; **P < .01; ****P < .0001 via Wilcoxon signed rank test) combination of the two mechanisms may make more sense than either in isolation, though. Generalized B-cell activation mediated by the autoimmune repertoire will require systematic longitudinal studies of antigen-specific memory and ASC cells, a rather difficult study which will be facilitated by the ability to identify SLE-specific autoreactivities with the 9G4 idiotype and will be discussed further below.
| CLONAL PER S IS TEN CE IN S LE: IMMUNOLOG IC AL IMPLIC ATIONS
The previously described ASC repertoire in SLE is characterized by limited clonal dominance, low mutation frequency, and clonal re- 
| UNDERSTANDING THE CONTRIBUTI ON OF NAIVE B CELL S TO S LE
Our previous studies demonstrated that the contribution of naive B cells to the generation of ASC during lupus flares was accounted for 
| S ELEC TI ON OF VH4 -3 4 -EN CODED AUTOANTIBOD IE S IN S LE
Among the more than 100 autoantibody species identified in SLE, only a selected few have >95% specificity for the disease. SLE-specific autoantibodies include anti-dsDNA, anti-Smith, anti-ribosomal P, and antibodies encoded by the VH4-34 gene segment (VH4-34 antibodies). In the unmutated germline configuration, VH4-34 antibodies are recognized by the 9G4 rat anti-human idiotype mAb which binds a hydrophobic patch (HP) within the framework-1 region (FR1 of total IgG and a substantial fraction of anti-dsDNA antibodies. 15, 62 In addition, we have shown that VH4-34 antibodies contribute the F I G U R E 4 Heavy-chain immunoglobulin transcript sequencing was conducted on an SLE subject in April of 2013 and then again using 10x Genomics' emulsion-based paired chain sequencing method on a separate January of 2018 sample collection. In this figure, clones from both longitudinal samples and a sample from a separate SLE subject were individually size-ranked and plotted along the outer track. Clones matching in multiple samples were then connected by the inner lines. . Percent of VH4-34 sequences without HP mutations are plotted for each B-cell population in SLE and healthy subjects (n = 16 healthy naive; 14 SLE naive; 4 healthy UnSw; 6 SLE UnSw; 16 healthy SwM; 29 SLE SwM; 14 healthy ASC; 11 SLE ASC; *P < .05; **P < .01; ****P < .0001 via Wilcoxon signed rank test) editors, where certain light chains modify binding properties of the heavy chain, 67, 68 or the use of particular HCDR3s. Ultimately, the contribution of different mechanisms to prevent VH4-34-mediated autoimmunity will have to be assessed by high-throughput analysis of single memory cells and PC obtained from peripheral and BM compartments. Such studies are underway in our laboratory using the approaches illustrated in Figure 1 .
Perhaps not surprisingly, our NGS work also indicates that clonal redemption is less effective in SLE with as much as 75% of VH4-34 memory cells and ASC retaining the HP. These data are quite consistent with our previous single-cell analysis showing preservation of the HP in the majority (average 75%) of SLE memory cells. 69 Nevertheless, it is important to consider that in the absence of the HP, VH4-34 B cells can also react with other important SLE autoantigens including dsDNA, Smith, and apoptotic cells. Therefore, we believe that our data indicate a role for selective pressure to retain this germline-encoded region even in the presence of extensive SHM. As stated earlier, extensive single-cell analysis will be required to clarify this important question and overall, to ascertain whether the selection of pathogenic VH4-34 clones in SLE is mostly driven by affinity maturation against the original antigen or, instead, involves diversification through selection of mutated clones by separate antigens.
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